H. Lundbeck ASHLUBF 78 Interest Coverage is 74.32 as of Mar. 2026, which is 255% above its 10-year median of 20.95. GuruFocus rates HLUBF with a GF Score™ of 78/100 and a GF Value™ of $5.65 (Fairly Valued). The stock has 3 warning signs investors should review. Among 686 Drug Manufacturers companies, H. Lundbeck AS ranks worse than 55.25% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. H. Lundbeck AS's
Operating Income
for the
three
months ended in Mar. 2026 was $333 Mil. H. Lundbeck AS's Interest Expense for the
three
months ended in Mar. 2026 was $-4 Mil.
H. Lundbeck AS's interest coverage for the quarter that ended in Mar. 2026 was 74.32.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for H. Lundbeck AS's Interest Coverage or its related term are showing as below:
HLUBF'
s Interest Coverage Range Over the Past 10 Years
Min: 7.47 Med: 20.95 Max: 1264.75
Current: 9.87
HLUBF's Interest Coverage is ranked worse than 55.25% of 686
companies
in the Drug Manufacturers industry
Industry Median: 12.725
vs HLUBF: 9.87
H. Lundbeck AS (OTCPK:HLUBF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
H. Lundbeck AS Interest Coverage Related Terms
H. Lundbeck AS Interest Coverage Historical Data
* Premium members only.
The historical data trend for H. Lundbeck AS's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HLUBF vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H. Lundbeck AS Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Interest Coverage distribution charts can be found below:
* The bar in red indicates where H. Lundbeck AS's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
H. Lundbeck AS (HLUBF) has a Interest Coverage of 74.32 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on H. Lundbeck AS and its competitors. This is 255% above median its historical median of 20.95. Over the past decade, H. Lundbeck AS's Interest Coverage has ranged from 7.47 to 1,264.75. According to the industry distribution chart, H. Lundbeck AS ranks #379 out of 686 companies in the Drug Manufacturers industry, placing it in the top 55.2%.
Is H. Lundbeck AS's Interest Coverage too high?
H. Lundbeck AS's current Interest Coverage of 74.32 is 255% above median its 10-year median of 20.95. Over the past 10 years, this metric has ranged from a low of 7.47 to a high of 1,264.75. The Drug Manufacturers industry median Interest Coverage is 12.73. H. Lundbeck AS's value of 74.32 is 484% above this industry median. Based on the distribution chart, H. Lundbeck AS ranks #379 out of 686 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #379 out of 686 companies for Interest Coverage. This places H. Lundbeck AS in the lower half of its industry. The industry median Interest Coverage is 12.73. H. Lundbeck AS's value of 74.32 is 484% above this benchmark. Historically, H. Lundbeck AS's own Interest Coverage has ranged from 7.47 to 1,264.75 over the past decade. While the company's 10-year median is 20.95 vs. the industry median of 12.73, H. Lundbeck AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current Interest Coverage of 74.32 is 484% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on H. Lundbeck AS and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current Interest Coverage is 74.32, which is 255% above median its own 10-year median of 20.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (HLUBF) is currently considered Fairly Valued. The stock's GF Value™ is $5.65, compared to a current price of $5.50 — trading 2.7% below its estimated fair value. The current Interest Coverage is 74.32, which is 255% above median its 10-year median of 20.95 and 484% above the Drug Manufacturers industry median of 12.73. H. Lundbeck AS's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For H. Lundbeck AS (HLUBF), the current Interest Coverage is 74.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (HLUBF) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued.
The current stock price of $5.50 is trading 2.7% below its estimated GF Value™ of $5.65.
GuruFocus considers H. Lundbeck AS to be Fairly Valued.
Key valuation signals for HLUBF:
Interest Coverage: 74.32 (255% above median its 10-year median of 20.95)
GF Value™: $5.65 vs. price of $5.50 (2.7% below fair value)
Industry Position: 484% above the Drug Manufacturers median (#379 of 686)
No single metric tells the full story. See the HLUBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
78GF Score
Get the complete analysis for HLUBF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLUBF has been successfully added to your 
